Interview: Mike Harsh on the evolution of Imaging and Imagion’s role
With over 40 years’ experience in the health care diagnostic imaging industry, Imagion Biosystems (ASX:IBX) Board member Mike Harsh is one of the world’s most qualified people to speak about the evolution of diagnostics.
Finfeed‘s Jonathan Jackson sat down with a very enthusiastic Harsh to discuss the industry, the limited ways to image the human body (X-ray, CT, MRI, ultrasound, and PET/SPECT) and how Imagion is reimagining the process.
Read the interview.
Prestige Biopharma and Imagion Biosystems Sign an MOU, Developing Early Pancreatic Cancer Diagnosis Platform
SINGAPORE, and San Diego, California – Prestige Biopharma, a biopharmaceutical company specializing in innovative antibody therapies, with a strong dedication to tackling pancreatic cancer, and Imagion